Melbourne Eye Vet, Mulgrave, Australia.
The Rabbit Doctors, Collingwood, Australia.
Open Vet J. 2022 Nov-Dec;12(6):822-829. doi: 10.5455/OVJ.2022.v12.i6.6. Epub 2022 Nov 11.
Glaucoma is a painful and blinding condition that occurs in many species, including rabbits. When medication is no longer effective in maintaining intraocular pressure (IOP), enucleation is the recognized treatment for rabbits with end-stage glaucoma. However, this procedure carries risks relating to the procedure and the anesthesia.
The aim of this retrospective study was to report the efficacy of intravitreal gentamicin injection in controlling IOP in blind eyes of rabbits with end-stage glaucoma. Ocular and non-ocular complications were retrospectively assessed.
Medical record review was performed to identify five client-owned rabbits (eight eyes) that were treated by intravitreal injection of 6-20 mg of gentamicin per eye (median 7.18 mg/kg) for chronic, end-stage glaucoma. Treatment was unilateral in two and bilateral in three rabbits. IOP control was assessed via rebound tonometry readings performed approximately 2 weeks, 1 month, 3 months, and 6 months after injection. Total follow-up was between 313 and 1,111 days. Ocular complications were recorded and systemic health was estimated by the owner-answered questionnaire and changes in body weight.
IOP was <25 mmHg in 87.5% of eyes 3 months post-injection. The most common ocular complications were cataracts (62.5%), anterior uveitis (25%), retinal detachment (12.5%), and corneal erosion (12.5%). There were no behavioral or body weight changes suggestive of systemic complications.
87.5% of rabbit eyes treated with intravitreal gentamicin had controlled IOP 3 months after injection. All eyes were blind at the time of injection. Ocular side effects were common. Investigation of the safety and systemic effects of intravitreal gentamicin injection is required; however, no overt complications were identified in treated rabbits in this study.
青光眼是一种在许多物种中发生的痛苦和致盲的疾病，包括兔子。当药物不再有效维持眼内压（IOP）时，眼球摘除术是患有晚期青光眼的兔子的公认治疗方法。然而，该手术涉及到手术和麻醉的风险。
本回顾性研究旨在报告玻璃体内庆大霉素注射控制晚期青光眼兔失明眼眼压的疗效。回顾性评估眼部和非眼部并发症。
对五名患有慢性、晚期青光眼的宠物兔（八只眼）进行了回顾性评估，这些兔子通过每只眼注射 6-20 毫克庆大霉素（中位数 7.18 毫克/公斤）进行治疗。在两只兔子中单侧治疗，在三只兔子中双侧治疗。注射后约 2 周、1 个月、3 个月和 6 个月进行眼压反弹测量评估眼压控制情况。总随访时间为 313 至 1111 天。记录眼部并发症，并通过主人回答问卷和体重变化评估全身健康状况。
87.5%的眼睛在注射后 3 个月眼压<25mmHg。最常见的眼部并发症是白内障（62.5%）、前葡萄膜炎（25%）、视网膜脱离（12.5%）和角膜侵蚀（12.5%）。没有行为或体重变化提示存在全身并发症。
玻璃体内注射庆大霉素治疗的 87.5%的兔子在注射后 3 个月眼压得到控制。所有眼睛在注射时已经失明。眼部副作用很常见。需要进一步研究玻璃体内庆大霉素注射的安全性和全身效应；然而，在本研究中，接受治疗的兔子没有明显的并发症。
